The time course of recovery of [3H~spiperone binding in the rat striatum after a single injection of the irreversible antagonist N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ) shows that a slower rate of regeneration/turnover of D-2 dopamine receptors occurs in mid-lifemature versus young male rats. This slower receptor recovery reflects relatively slower rates of both receptor synthesis and degradation. Studies using cycloheximide indicate that protein synthesis plays a significant role in the reappearance of
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[FH]spiperone-binding sites. Other experiments indicate that chronic reserpine treatment, which produces dopamine receptor up regulation, also produces accelerated receptor recovery after EEDQ blockade. An age-related decline in dopamine receptor turnover, if present in humans and progressive into senescence, could be responsible for the increased risk of developing Parkinson disease and drug-induced parkinsonian-like extrapyramidal side effects with age. On the other hand, the more rapid receptor turnover rates seen in young rats may be a biochemical feature related to plasticity in the striatum during development.
Age-related differences in therapeutic dosages and extrapyramidal side effects have been reported for the clinical use of antipsychotic drugs (1, 2) . Since these agents are hypothesized to exert their therapeutic as well as extrapyramidal side effects by blocking dopamine receptors in the brain, one might expect the regulation of functional levels or other properties of these dopamine receptors to exhibit age-dependent differences. Indeed, dopamine receptor levels in rat striatum have been observed to increase over the first month postnatally (3), and age-correlated losses of dopaminergic receptor-binding activity and function have been noted in humans and rodents (for review, see refs. 2 and 4) . In aged rodents relative deficits in the ability of dopamine receptors to exhibit up regulation in response to chronic dopamine receptor antagonist (antipsychotic) drug treatments have been described (5) , although other researchers have not observed such aging-related deficits in dopamine receptor up regulation when more robust (lesion-induced) decreases in agonist input were used (6) (7) (8) (9) .
Aging-related deficits in the ability of 83-adrenergic receptor to exhibit up regulation have also been described (10) (11) (12) . A recent report described aging-related decreases in the regeneration of visceral beta-adrenergic receptors after their irreversible blockade (13) , thus suggesting one possible mechanism for the observed age-related deficits in receptor up regulation. A vehicle and decapitated at various times. For time-course experiments, rats were sacrificed at the same time of day 6, 28-30, 52-54, 100-102, 148-150, and 172-174 hr after injection with either EEDQ or vehicle. Their brains were rapidly removed and placed in ice-cold saline, and their striata were dissected and stored frozen at -70'C for up to 6 days. An EEDQ dose of 8 mg/kg was chosen because it produced near maximal receptor blockade but only a moderate mortality rate (10-15%), as noted by Hamblin and Creese (14) . These deaths may be related to the potent and long-lasting hypotensive effects of EEDQ combined with the hypotensive actions of both components of the vehicle. In addition, a significant portion ('20%) of the EEDQ-injected rats did not become cataleptic and concomitantly exhibited much lower or no inhibition of [3H]spiperone binding. Thus, these animals were excluded from further analysis. The failure of EEDQ to block D-2 receptors in these rats may be related to the known instability of this compound in aqueous solution (refs. 15, 16, and 19 ; also see Discussion).
Cycloheximide Treatment. Cycloheximide (360 ,ug in 30 ,ul saline) or saline only was injected under ether anesthesia into the left lateral ventricle (1.5 mm left of the midline, 0.5-1.5 mm caudal of the bregma suture) with a 27-gauge needle fitted with a shrink tube stop 4.0 mm from the tip (20 binding) to yield a final assay volume of 2 ml and a final tissue concentration of 1.35 mg/ml. Tubes were incubated 15 min at 37°C before filtration over GF/C glass fiber filters (Whatman) under vacuum using a Brandel automated cell harvester modified for receptor-binding assays. Filters were rapidly washed with 10 ml of ice-cold Tris buffer and trapped radioactivity was determined by standard scintillation spectroscopy.
Radioreceptor Assays. Blood samples from EEDQ-or vehicle-injected rats were collected by exsanguination and allowed to clot before centrifugation for 5 min at 400 g at 4°C. Serum samples were reserved on ice and serum from untreated rats was used as diluent for serial dilution of EEDQ. Membrane preparations of rat striata were washed once with 50 mM Tris HCl (pH 7.7 at 25°C) and then suspended in 40 vol of Tris buffer containing 120 mM NaCl, 5 mM KCI, 2 mM CaC12, and 1 mM MgCl2. To 1.0-ml volumes of this suspension were added 1.0 ml of serum samples containing standard or unknown concentrations of EEDQ. These reaction mixtures were allowed to incubate for 30 min at 37°C at which time the reaction was quenched with 10 ml of ice-cold Tris buffer. Membranes were subsequently centrifuged twice more with an intervening suspension in cold Tris buffer. Final homogenates were made in the assay buffer described earlier and placed in triplicate tubes containing (final assay concentrations) 0.5 nM [3H]spiperone, 50 nM ketanserin, and either ascorbic acid (total determinations) or (+)butaclamol (1 ,uM; nonspecific determination). Unknown serum samples were compared with standards, and concentrations of "EEDQ activity" were defined in terms of ,ug equivalents per ml.
Data Analysis. Receptor densities and affinity estimates were determined by computer analysis using LIGAND, a weighted nonlinear least-squares curve-fitting program (23) as described in detail (24) . For convenience, saturation data are graphically displayed in the form of Scatchard plots (25) . Tabulated [1] where [RJ = receptor concentration at time t, r = receptor production rate, and k = rate constant for receptor degradation (26, 27) . As the time of repopulation proceeds to infinity, [R,] approaches the value r/k and therefore approaches [R]j, the concentration of receptor at steady state. Logarithmic transformation (27) Plots of our receptor recovery data according to Eq. 2 are shown in Fig. 3 . The slopes of these plots, which are estimates of their respective receptor-degradation rate constants (k), are significantly different for the two age groups (F = 3.6, df = 54, P < 0.001; two-way ANOVA Effects of Chronic Reserpine Treatment on Recovery of (3HJSpiperone Binding After EEDQ Treatment. To determine whether D-2 dopamine receptor turnover rates could be modulated by chronic changes in dopaminergic transmission in the striatum, rats were injected daily with the catecholamine-depleting agent reserpine. Chronic treatment with this drug has been shown previously to produce a significant increase in D-2 dopamine receptor-binding sites in the striatum (28) . Results from an investigation of whether this D-2 dopamine receptor "up regulation" is associated with a change in receptor recovery rates are shown in Table 2 Results represent mean ± SEM. Acute cycloheximide treatment had no significant effect on [3H]spiperone binding in control rats, but long-term cycloheximide treatment impaired receptor recovery when started 12 hr after EEDQ treatment. *P < 0.004 by Mann-Whitney U test, one-tailed. Chronic reserpine treatment (19 days) produced D-2 dopamine receptor up regulation and accelerated D-2 receptor turnover as measured by recovery from EEDQ blockade. Daily reserpine (Serpasil) or saline injections (0.25 mg/kg, s.c.) were administered throughout the experiment. On day 17, EEDQ or vehicle was injected and rats were sacrificed at times indicated. Results represent mean ± SEM and were analyzed by paired t test (two-tailed). *Not significant. tp < 0.01. tP < 0.001. concentrations were 31.5% higher in reserpine versus salinetreated rats 54 hr after EEDQ treatment (P < 0.01, twotailed paired t test). This may reflect an acceleration in D-2 dopamine receptor turnover or synthesis rate in these rats.
DISCUSSION
We have shown that the rate of recovery of D-2 dopamine receptor-binding activity after irreversible blockade in the neostriatum is slower in mid-life/mature than in young rats.
The receptor recovery curves for both age groups were analyzed according to a simplified receptor repopulation model previously described for nicotinic cholinergic (29) , insulin (30, 31) , and a1-adrenergic receptors (26, 27) . This model assumes a linear receptor production rate (r) and an exponential receptor degradation rate constant (k). Although more complex models might also fit the data, the relatively linear relationships shown in Fig. 3 (correlation coefficient = 0.75 and 0.935 for young and old rats, respectively) suggest that Eq. 1 is a valid first approximation of D-2 receptor repopulation kinetics in striatum after EEDQ blockade.
We attempted to determine whether the recovery of D-2 receptor-binding sites is dependent on protein synthesis and thus, perhaps, de novo receptor synthesis. Table 1 shows that administration of cycloheximide during recovery from EEDQ-induced receptor loss significantly lowered densities of striatal [3Hijspiperone-binding sites. These data are consistent with the hypothesis that protein synthesis of de novo receptor is involved in the regeneration of D-2 dopamine receptors after irreversible blockade. However, it is possible that ongoing protein synthesis supports some other function, such as insertion of already existing receptors into the membrane, rather than simply de novo synthesis of D-2 dopamine receptors. While it cannot be ascertained that these effects of cycloheximide are specific to its activity as an inhibitor of protein synthesis, controls indicated that cycloheximide exerted no direct inhibition of [3HUspiperone binding.
It was considered that differential rates of EEDQ metabolism, should they occur in young and old rats, might account for their respective differences in receptor recovery. Several lines of evidence argue against this possibility. First, the slopes of the receptor recovery curves over time (Fig. 2) differ for the two age groups of rats studied. A simple right shift of the curve for mature versus young rats might be expected if slower EEDQ metabolism was the primary factor in their slower recovery rates. Second, EEDQ is unstable in aqueous solution (15, 16, 19) and probably undergoes rapid catabolism due to hydrolysis and reaction with serum and tissue proteins. Radioreceptor assays suggest that serum EEDQ declines to insignificant levels by 30 min after injection.
Since this rapid catabolism (measured in minutes) was observed in mature rats, which might be predicted to metabolize EEDQ more slowly, it is unlikely that different rates of EEDQ metabolism are the explanation for the slower D-2 dopamine receptor regeneration rate (measured in days) observed in older rats. Evidence that similar intracerebral EEDQ levels were achieved in both age groups of rats after injection derives from the observation that the initial inhibition of [3H]spiperone binding in both age groups was similar (85-90%; Fig. 2) .
The half-lives of D-2 dopamine receptors estimated in the present study for either young or old male rats differ considerably from the t½ of 8-9 hr recently reported by Hall et al. (32) . The reason for this discrepancy is unclear, but it may be related to a number of differences in our studies. First, Hall et al., using a different alkylating agent (phenoxybenzamine), reported a lesser maximal inhibition (75%) of specific [3H]spiperone binding than we observed. It remains to be determined whether a relationship exists between completeness of blockade and t½ of receptor recovery. However, in another study McKernan have affected their results. Third, their protocol utilized two injections of phenoxybenzamine given 12 hr apart, compared with our single injection of EEDQ. Last, their study was conducted on 150-g female rats. It should also be considered that the alkylation of receptors may influence receptor turnover.
The significance of the age-related differences we observed in Kd values for the antagonist [3H]spiperone is unclear. Indeed the control animals from our studies using cycloheximide or reserpine were only 30-55 days old and exhibited Kd values ranging from 40 to 100 x 10-12 M (Tables 1  and 2 ). Thus absolute Kd values can be variable at any age when measured in different experiments. The slight but significant effects of EEDQ treatment on [3H]spiperone Kd values are equally unclear. It would be premature to suggest that residual nonalkylated or regenerated D-2 receptors represent pharmacologically or biochemically distinct receptor subtypes.
The functional significance of the more rapid receptor turnover rate we observed in young rats is unknown. One might speculate that the faster receptor synthesis and degradation rates we observed in young rats may reflect the presence of a greater degree of plasticity in the striatum at this age. Nevertheless, the more rapid turnover rate in young rats is consistent with previous ontogenetic findings indicating that D-2 dopamine receptor levels are terminating their rapid increase from neonatal to adult levels (3). Our observation that control young rats exhibited lower Bmax values than mature rats suggests that their receptor levels were below the maximum levels observed in young adults because Bmax values are reported to be lower in mature rats when compared with young adults (reviewed in refs. 2 
